Consensus statement of the spanish society of rheumatology on risk management of biologic therapy in rheumatic patients;Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas

Reumatologia Clinica

Volumn 7, Issue 5, 2011, Pages 284-298

  Reino, Juan Gómez ^a   Loza, Estíbaliz ^b   Andreu, José Luis ^c   Balsa, Alejandro ^d   Batlle, Enrique ^e   Cañete, Juan D ^f   Collantes Estévez, Eduardo ^g   Fernández Carballido, Cristina ^h   Fernández Sueiro, José Luis ⁱ   García de Vicuña, Rosario ^j   González Álvaro, Isidoro ^j   González Fernández, Carlos ^k   Juanola, Xavier ^f   Linares, Luis Francisco ^l   Marenco, José Luis ^m   Martín Mola, Emilio ^d   Moreno Ramos, Manuel ^m   Mulero Mendoza, Juan ^c   Muñoz Fernández, Santiago ^o   Queiro, Rubén ^p   Richi Alberti, Patricia ⁿ   Sanz, Jesús ^c   Tornero Molina, Jesús ^q   Zarco Montejo, Pedro ^r   Carmona, Loreto ^s   more..

^a University Hospital of Santiago de Compostela   (Spain)

^b UNIDAD DE INVESTIGACIÓN   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^d HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^e HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^h HOSPITAL GENERAL DE ELDA   (Spain)

ⁱ UNIVERSITY OF A CORUÑA   (Spain)

^j HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^m HOSPITAL UNIVERSITARIO DE VALME   (Spain)

ⁿ Allergy Section   (Spain)

^o HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

^p HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^q HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^r HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^s CAMILO JOSÉ CELA UNIVERSITY   (Spain)

more..

Author keywords

Biologic therapy; Consensus; Guidelines; Recommendations; Rheumatic diseases; Risk management; Systemic autoimmune diseases

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; CHICKENPOX VACCINE; DENOSUMAB; DIPHTHERIA VACCINE; ETANERCEPT; GOLIMUMAB; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INFLIXIMAB; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MENINGOCOCCUS VACCINE; METHOTREXATE; METHYLPREDNISOLONE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PERTUSSIS VACCINE; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TETANUS TOXOID; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; WART VIRUS VACCINE;

ABDOMINAL PAIN; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANKYLOSING SPONDYLITIS; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; BACTERIAL INFECTION; BILIRUBIN BLOOD LEVEL; BIOLOGICAL THERAPY; CATARACT; CELLULITIS; CLINICAL PROTOCOL; CONGESTIVE HEART FAILURE; CONSENSUS; CYTOPENIA; DELPHI STUDY; DEPRESSION; DIARRHEA; DIVERTICULITIS; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SURVEILLANCE PROGRAM; DYSPNEA; EAR INFECTION; ECZEMA; EMPHYSEMA; FATIGUE; FEVER; FOLLOW UP; GENITAL HERPES; HEADACHE; HEALTH CARE ORGANIZATION; HEART ARRHYTHMIA; HEART DISEASE; HEART PALPITATION; HEMORRHOID; HEPATITIS; HEPATITIS B; HERPES SIMPLEX; HUMAN; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; HYPOCALCEMIA; INFECTION; INFUSION REACTION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; ISCHIALGIA; JUVENILE RHEUMATOID ARTHRITIS; LEUKOPENIA; LIMB PAIN; LYMPHOMA; MELANOMA; MIGRAINE; MULTIPLE SCLEROSIS; MUSCLE CRAMP; MYALGIA; NAUSEA; NEOPLASM; NEUTROPENIA; OSTEOPOROSIS; PANCYTOPENIA; PARESTHESIA; PAROSMIA; PATIENT ATTITUDE; PNEUMONIA; PRACTICE GUIDELINE; PSORIASIS; PSORIATIC ARTHRITIS; RASH; RESPIRATORY TRACT INFECTION; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK MANAGEMENT; SEPSIS; SEPTICEMIA; SIDE EFFECT; SKIN CANCER; SKIN INFECTION; SOLID TUMOR; SYSTEMATIC REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THORAX PAIN; THROMBOCYTOPENIA; TUBERCULOSIS; URINARY TRACT INFECTION; VERTIGO; VIRUS INFECTION; VOMITING;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; BIOLOGICAL THERAPY; DELPHI TECHNIQUE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PHARMACOVIGILANCE; RHEUMATIC DISEASES; RISK MANAGEMENT;

EID: 80052971454     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2011.05.002     Document Type: Article

References (109)

1. Tornero J., Sanmartí R., Rodríguez V., Martín E., Marenco J.L., González-Álvaro I., et al. Actualización del Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de terapias biológicas en la artritis reumatoide. Reumatol Clin 2010, 6:23-36.
2. Sociedad Española de Reumatología. Guía de práctica clínica para el manejo de la Artritis Reumatoide 2007 (Versión HTML completa). 2007 [citado 22 Sept 2009]; Disponible en: http://www.ser.es/practicaClinica/GUIPCAR_2007/Menu0_Principal.php.
3. Sociedad Española de Reumatología. Guía de práctica clínica sobre el manejo de los pacientes con espondiloartritis (ESPOGUIA) 2010 [citado 20 Ago 2010]; Disponible en: http://www.ser.es/practicaClinica/espoguia/index.php.
4. Braun J., Pham T., Sieper J., Davis J., van der Linden S., Dougados M., International ASAS, et al. consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003, 62:817-824.
5. Gómez-Reino J.J., Carmona L., Ángel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007, 57:756-761.
6. Gossec L., Dougados M., Phillips C., Hammoudeh M., de Vlam K., Pavelka K., et al. Dissemination and evaluation of the ASAS/EULAR recommendations for the management of ankylosing spondylitis: results of a study among 1507 rheumatologists. Ann Rheum Dis 2008, 67:782-788.
7. CEBM CfEBM. Oxford Centre for Evidence-based Medicine - Levels of Evidence (March 2009). 2009 [actualizado marzo 2009; citado 2 Nov 2009]; Disponible en: http://www.cebm.net/index.aspx%3Fo=1025.
8. Agencia Española del Medicamento y Productos Sanitarios. Disponible en: http://www.aemps.es/profHumana/farmacovigilancia/home.htm.
9. Carmona L., Descalzo M.A., Ruiz-Montesinos D., Manero-Ruiz F.J., Pérez-Pampin E., Gómez-Reino J.J. Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. Rheumatology (Oxford) 2011, 50:85-92.
10. Braun J., Baraliakos X., Listing J., Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005, 52:2447-2451.
11. Sieper J., Koenig A., Baumgartner S., Wishneski C., Foehl J., Vlahos B., et al. Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 2010, 69:226-229.
12. Reumatología SER. Folletos de la SER. Madrid 2011; Disponible en: http://www.ser.es/pacientes/consultas_recursos/folleto.php.
13. Carmona L, Gómez-Reino J, González R, BIOBADASER Gde. Spanish registry for adverse events of biological therapies in rheumatic diseases (BIOBADASER): State report as of January 14th 2005. Reumatol Clin. 2005;1:95-111.
14. Furst D.E., Schiff M.H., Fleischmann R.M., Strand V., Birbara C.A., Compagnone D., et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003, 30:2563-2571.
15. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
16. Breedveld F.C., Emery P., Keystone E., Patel K., Furst D.E., Kalden J.R., et al. Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 2004, 63:149-155.
17. Strangfeld A., Listing J., Herzer P., Liebhaber A., Rockwitz K., Richter C., et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009, 301:737-744.
18. Khanna D., McMahon M., Furst D.E. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004, 27:307-324.
19. Cohen S.B., Emery P., Greenwald M.W., Dougados M., Furie R.A., Genovese M.C., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006, 54:2793-2806.
20. Smolen J.S., Beaulieu A., Rubbert-Roth A., Ramos-Remus C., Rovensky J., Alecock E., et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008, 371:987-997.
21. Fleischmann R., Vencovsky J., van Vollenhoven R.F., Borenstein D., Box J., Coteur G., et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009, 68:805-811.
22. Keystone E., Genovese M.C., Klareskog L., Hsia E.C., Hall S., Miranda P.C., et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. Ann Rheum Dis 2010, 69:1129-1135.
23. Baeten D., Kruithof E., Van den Bosch F., Van den Bossche N., Herssens A., Mielants H., et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?. Ann Rheum Dis 2003, 62:829-834.
24. Van Den Bosch F., Kruithof E., Baeten D., Herssens A., de Keyser F., Mielants H., et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002, 46:755-765.
25. Mease P.J., Kivitz A.J., Burch F.X., Siegel E.L., Cohen S.B., Ory P., et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264-2272.
26. Pena-Sagredo J.L., Farinas M.C., Pérez-Zafrilla B., Cruz-Valenciano A., Crespo M., Joven-Ibáñez B., et al. Non-typhi Salmonella infection in patients with rheumatic diseases on TNF-alpha antagonist therapy. Clin Exp Rheumatol 2009, 27:920-925.
27. Alonso-Ruiz A., Pijoan J.I., Ansuategui E., Urkaregi A., Calabozo M., Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord 2008, 9:52.
28. Solomon D.H. The comparative safety and effectiveness of TNF-alpha antagonists [corrected]. J Manag Care Pharm 2007, 13(1 Suppl):S7-S18.
29. Gómez-Reino J.J., Carmona L., Valverde V.R., Mola E.M., Montero M.D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127.
30. Keane J., Gershon S., Wise R.P., Mirabile-Levens E., Kasznica J., Schwieterman W.D., et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001, 345:1098-1104.
31. Mohan A.K., Cote T.R., Block J.A., Manadan A.M., Siegel J.N., Braun M.M. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004, 39:295-299.
32. Carmona L., Gómez-Reino J.J., Rodríguez-Valverde V., Montero D., Pascual-Gómez E., Mola E.M., et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005, 52:1766-1772.
33. Ena J., Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005, 40:670-676.
34. Scott D.L., Kingsley G.H. Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006, 355:704-712.
35. Sibilia J., Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007, 25(5 Suppl 46):S46-S56.
36. Chakravarty E.F., Michaud K., Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. J Rheumatol 2005, 32:2130-2135.
37. Geborek P., Bladstrom A., Turesson C., Gulfe A., Petersson I.F., Saxne T., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005, 64:699-703.
38. Okada S.K., Siegel J.N. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 2006, 296:2201-2202.
39. Wolfe F., Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50:1740-1751.
40. Askling J., Fored C.M., Baecklund E., Brandt L., Backlin C., Ekbom A., et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64:1414-1420.
41. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
42. Askling J., Klareskog L., Blomqvist P., Fored M., Feltelius N. Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study. Ann Rheum Dis 2006, 65:1184-1187.
43. Setoguchi S., Schneeweiss S., Avorn J., Katz J.N., Weinblatt M.E., Levin R., et al. Tumor necrosis factor-alpha antagonist use heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008, 156:336-341.
44. Curtis J.R., Kramer J.M., Martin C., Saag K.G., Patkar N., Shatin D., et al. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) 2007, 46:1688-1693.
45. Singh J.A., Wells G.A., Christensen R., Tanjong Ghogomu E., Maxwell L., Macdonald J.K., et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011, 2:CD008794.
46. Martin L., Barr S., Green F., Fritzer M. Severe fatal complications associated with infliximab therapy in rheumatoid arthritis. J Rheumatol 2006, 33:380.
47. Ostor A.J., Chilvers E.R., Somerville M.F., Lim A.Y., Lane S.E., Crisp A.J., et al. Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis. J Rheumatol 2006, 33:622-628.
48. Cruz Fernández-Espartero M., Pérez-Zafrilla B., Naranjo A., Esteban C., Ortiz A.M., Gómez-Reino J.J., et al. Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review. Semin Arthritis Rheum 2010, 40:330-337.
49. Simsek I., Erdem H., Pay S., Sobaci G., Dinc A. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. Ann Rheum Dis 2007, 66:1255-1258.
50. Bensouda-Grimaldi L., Mulleman D., Valat J.P., Autret-Leca E. Adalimumab-associated multiple sclerosis. J Rheumatol 2007, 34:239-240.
51. Calabrese L.H., Zein N.N., Vassilopoulos D., Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006, 65:983-989.
52. Wendling D., Auge B., Bettinger D., Lohse A., Le Huede G., Bresson-Hadni S., et al. Reactivation of a latent precore mutant hepatitis B virus related chronic hepatitis during infliximab treatment for severe spondyloarthropathy. Ann Rheum Dis 2005, 64:788-789.
53. Carroll M.B., Forgione M.A. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol 2010, 29:1021-1029.
54. Evens A.M., Jovanovic B.D., Su Y.C., Raisch D.W., Ganger D., Belknap S.M., et al. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2010, 22:1170-1180.
55. Parke F.A., Reveille J.D. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004, 51:800-804.
56. Zein N.N. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol 2005, 42:315-322.
57. Cansu D.U., Kalifoglu T., Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008, 35:421-424.
58. Ferri C., Ferraccioli G., Ferrari D., Galeazzi M., Lapadula G., Montecucco C., et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008, 35:1944-1949.
59. Mahajan T.D., Hooker R., Maher L., Brown G., Reimold A. Abatacept therapy for rheumatoid arthritis in the setting of hepatitis C infection. J Clin Rheumatol 2010, 16:332-334.
60. Saadoun D., Resche-Rigon M., Sene D., Perard L., Karras A., Cacoub P. Rituximab combined with Peg-interferon-ribavirin in refractory hepatitis C virus-associated cryoglobulinaemia vasculitis. Ann Rheum Dis 2008, 67:1431-1436.
61. Sene D., Ghillani-Dalbin P., Amoura Z., Musset L., Cacoub P. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis. Arthritis Rheum 2009, 60:3848-3855.
62. Cepeda E.J., Williams F.M., Ishimori M.L., Weisman M.H., Reveille J.D. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008, 67:710-712.
63. Kaine J.L., Kivitz A.J., Birbara C., Luo A.Y. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. Journal of Rheumatology 2007, 34:272-279.
64. Elkayam O., Caspi D., Reitblatt T., Charboneau D., Rubins J.B. The Effect of Tumor Necrosis Factor Blockade on the Response to Pneumococcal Vaccination in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis. Seminars in Arthritis and Rheumatism 2004, 33:283-288.
65. Elkayam O., Bashkin A., Mandelboim M., Litinsky I., Comaheshter D., Levartovsky D., et al. The Effect of Infliximab and Timing of Vaccination on the Humoral Response to Influenza Vaccination in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis. Semin Arthritis Rheum 2009, 39:442-447.
66. Tay L., Leon F., Vratsanos G., Raymond R., Corbo M. Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects. Arthritis Res Ther 2007, 9:R38.
67. Gelinck L.B.S., Teng Y.K.O., Rimmelzwaan G.F., Van Den Bemt B.J.F., Kroon F.P., Van Laar J.M. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Annals of the Rheumatic Diseases 2007, 66:1402-1403.
68. Oren S., Mandelboim M., Braun-Moscovici Y., Paran D., Ablin J., Litinsky I., et al. Vaccination against influenza in patients with rheumatoid arthritis: The effect of rituximab on the humoral response. Annals of the Rheumatic Diseases 2008, 67:937-941.
69. Ostensen M., Lockshin M., Doria A., Valesini G., Meroni P., Gordon C., et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 2008, 47(Suppl 3):iii28-iii31.
70. Vinet E., Pineau C., Gordon C., Clarke A.E., Bernatsky S. Biologic therapy and pregnancy outcomes in women with rheumatic diseases. Arthritis Rheum 2009, 61:587-592.
71. Temprano K.K., Bandlamudi R., Moore T.L. Antirheumatic drugs in pregnancy and lactation. Semin Arthritis Rheum 2005, 35:112-121.
72. Galloway J.B., Hyrich K.L., Mercer L.K., Dixon W.G., Fu B., Ustianowski A.P., et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2010, 50:124-131.
73. Keystone E., Fleischmann R., Emery P., Furst D.E., van Vollenhoven R., Bathon J., et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007, 56:3896-3908.
74. Fleischmann R.M., Schechtman J., Bennett R., Handel M.L., Burmester G.R., Tesser J., et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum 2003, 48:927-934.
75. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008, 67:1096-1103.
76. Smolen J.S., Kay J., Doyle M.K., Landewe R., Matteson E.L., Wollenhaupt J., et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009, 374:210-221.
77. Roll P., Rubbert-Roth A., Tony H.P. [Tocilizumab. What comes after TNF-blockers in clinical routine?]. Z Rheumatol 2010, 69:608-617.
78. Solovic I., Sester M., Gómez-Reino J.J., Rieder H.L., Ehlers S., Milburn H.J., et al. The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. Eur Respir J 2010, 36:1185-1206.
79. Askling J., Fored C.M., Brandt L., Baecklund E., Bertilsson L., Feltelius N., et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005, 64:1421-1426.
80. Simon T.A., Smitten A.L., Franklin J., Askling J., Lacaille D., Wolfe F., et al. Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment. Ann Rheum Dis 2009, 68:1819-1826.
81. Singh J.A., Beg S., López-Olivo M.A. Tocilizumab for Rheumatoid Arthritis: A Cochrane Systematic Review. J Rheumatol 2010, 38:10-20.
82. Strangfeld A., Hierse F., Rau R., Burmester G.R., Krummel-Lorenz B., Demary W., et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010, 12:R5.
83. Abasolo L., Judez E., Descalzo M.A., González-Álvaro I., Jover J.A., Carmona L. Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population. Semin Arthritis Rheum 2008, 37:388-397.
84. Dixon W.G., Hyrich K.L., Watson K.D., Lunt M., Symmons D.P. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010, 69:1086-1091.
85. Keystone E.C. Safety of biologic therapies-an update. J Rheumatol Suppl 2005, 74:8-12.
86. Wetter D.A., Davis M.D. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009, 84:979-984.
87. Ramos-Casals M., Brito-Zeron P., Soto M.J., Cuadrado M.J., Khamashta M.A. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol 2008, 22:847-861.
88. Ramos-Casals M., Brito-Zeron P., Munoz S., Soria N., Galiana D., Bertolaccini L., et al. Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. Medicine (Baltimore) 2007, 86:242-251.
89. Vassilopoulos D., Apostolopoulou A., Hadziyannis E., Papatheodoridis G.V., Manolakopoulos S., Koskinas J., et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2010, 69:1352-1355.
90. Sfikakis P.P., Iliopoulos A., Elezoglou A., Kittas C., Stratigos A. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. Arthritis Rheum 2005, 52:2513-2518.
91. Cohen J.D., Bournerias I., Buffard V., Paufler A., Chevalier X., Bagot M., et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 2007, 34:380-385.
92. Wollina U., Hansel G., Koch A., Schonlebe J., Kostler E., Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008, 9:1-14.
93. Fouache D., Goeb V., Massy-Guillemant N., Avenel G., Bacquet-Deschryver H., Kozyreff-Meurice M., et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 2009, 48:761-764.
94. Carter J.D., Ladhani A., Ricca L.R., Valeriano J., Vasey F.B. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol 2009, 36:635-641.
95. Paschou S., Voulgari P.V., Vrabie I.G., Saougou I.G., Drosos A.A. Fertility and reproduction in male patients with ankylosing spondylitis treated with infliximab. J Rheumatol 2009, 36:351-354.
96. Lamboglia F., D'Inca R., Oliva L., Bertomoro P., Sturniolo G.C. Patient with severe Crohn's disease became a father while on methotrexate and infliximab therapy. Inflamm Bowel Dis 2009, 15:648-649.
97. Montagna G.L., Malesci D., Buono R., Valentini G. Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents. Ann Rheum Dis 2005, 64:1667.
98. Wallace D.J. The use of etanercept and other tumor necrosis factor-alpha blockers in infertility: it's time to get serious. J Rheumatol 2003, 30:1897-1899.
99. Bibbo C., Goldberg J.W. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot and Ankle International 2004, 25:331-335.
100. Corrao S., Pistone G., Arnone S., Calvo L., Scaglione R., Licata G. Safety of etanercept therapy in rheumatoid patients undergoing surgery: Preliminary report. Clinical Rheumatology 2007, 26:1513-1515.
101. den Broeder A.A., Creemers M.C., Fransen J., de Jong E., de Rooij D.J., Wymenga A., et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007, 34:689-695.
102. Wendling D., Balblanc J.C., Brousse A., Lohse A., Lehuede G., Garbuio P., et al. Surgery in patients receiving anti-tumour necrosis factor (alpha) treatment in rheumatoid arthritis: An observational study on 50 surgical procedures. Annals of the Rheumatic Diseases 2005, 64:1378-1379.
103. Giles J.T., Bartlett S.J., Gelber A.C., Nanda S., Fontaine K., Ruffing V., et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. Arthritis Care and Research 2006, 55:333-337.
104. Ricci P., Patología Reumatológica, Importada Semin Fund Esp Reumatol 2010, 11:28-36.
105. Centers For Disease Control and Prevention. Parasites & Health. 2011 [citado2011]; Disponible en: http://www.dpd.cdc.gov/dpdx/HTML/Para_Health.htm.
106. Keiser P.B., Nutman T.B. Strongyloides stercoralis in the Immunocompromised Population. Clin Microbiol Rev 2004, 17:208-217.
107. Santiago M., Leitao B. Prevention of strongyloides hyperinfection syndrome: a rheumatological point of view. Eur J Intern Med 2009, 20:744-748.
108. Davis J.S., Currie B.J., Fisher D.A., Huffam S.E., Anstey N.M., Price R.N., et al. Prevention of opportunistic infections in immunosuppressed patients in the tropical top end of the Northern Territory. Commun Dis Intell 2003, 27:526-532.
109. Sánchez P.R., Guzmán A.P., Guillen S.M., Adell R.I., Estruch A.M., Gonzalo I.N., et al. Endemic strongyloidiasis on the Spanish Mediterranean coast. QJM 2001, 94:357-363.